Skip to main content
TipRanks
Go Ultimate75% OFF

Tactile Systems Technology (TCMD) AI Stock Analysis

461 Followers
TCMD

Tactile Systems Technology

(NASDAQ:TCMD)

Select Model
Rating:75Outperform
Price Target:$28.00â–²(6.18% Upside)
Action:reiterated
Date:11/04/26

The score is driven primarily by improved financial fundamentals (profitability turnaround, high gross margins, and a de-risked balance sheet) and supportive earnings guidance with raised adjusted EBITDA outlook. Technicals add a modest tailwind with improving near-term momentum, while valuation is a mild headwind given a 23.6 P/E and no dividend support. Airway-clearance weakness and some margin/cash-conversion softening temper the otherwise solid setup.

Positive Factors
Lymphedema growthSustained double-digit lymphedema growth demonstrates durable demand for Tactile Medical’s core therapy and continued market underpenetration. This momentum supports recurring device, garment, and accessory revenue while strengthening the company’s position in its primary treatment category.
Negative Factors
Airway-clearance weaknessThe airway-clearance business is facing a prolonged revenue headwind as DME customers work through excess inventory. Slower normalization and revenue below the prior year can dilute consolidated growth, reduce operating leverage, and increase dependence on lymphedema performance.

Tactile Systems Technology Key Performance Indicators (KPIs)

Revenue by ChannelShows how sales split across distribution routes—such as direct sales, distributors, clinics or online—revealing which channels drive growth, which are most scalable or profitable, and where the company is vulnerable to concentration or partner risk. Trending shifts between channels also indicate how well management can expand reach or control pricing and margins.

$0.00$25.00M$50.00M$75.00M$100.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Lymphedema is the durable growth engine—revenues across private payers and Medicare have trended higher and underpin management’s upgraded guidance—while airway‑clearance (DME) revenue is noisier and hit by temporary inventory management and Medicare prior‑authorization timing. The near‑term softness in the DME channel explains quarter‑to‑quarter volatility, but strong trailing‑12‑month AffloVest growth, next‑gen product rollout and new distribution deals point to normalization later in the year; channel concentration remains a risk until orders and DME inventory dynamics stabilize.

Data provided by:The Fly

Tactile Systems Technology (TCMD) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%40%TCMD+8.83%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$590.72M
Dividend Yield
―
Average Volume (3M)
260.47K
Price to Earnings (P/E)
25.1
Beta (1Y)
0.64
Revenue Growth
14.41%
EPS Growth
34.35%
Country
US
Employees
1,086
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Tactile Systems Technology Business Overview & Revenue Model

Company Description

Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compressi...

How the Company Makes Money

Tactile Systems Technology primarily makes money by selling pneumatic compression therapy systems (e.g., Flexitouch) and related consumable and replacement items such as garments, wraps, and accessories used with its devices. Revenue is generally gen...

Tactile Systems Technology Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q3-2026)|% Change Since:15.30%|Next Earnings Date:Feb 23, 2027
Earnings Call SentimentPositive

The call was predominantly positive, supported by sustained 13% lymphedema growth, broad commercial and Medicare gains, improved gross margin, strong cash generation, maintained revenue guidance and higher adjusted EBITDA guidance. The main challenges were the 25.1% airway-clearance revenue decline, the reduced airway-clearance outlook, lower quarterly operating income and net income, adjusted EBITDA margin compression, and the continued time required to improve referral conversion, payer coverage and new-product commercialization.

Positive Updates

Total Revenue Growth
Third-quarter total revenue was $91.9 million, up $6.1 million or 7.1% year-over-year, as double-digit lymphedema growth more than offset the expected decline in airway clearance. Year-to-date revenue increased 12% to $252.8 million.

Negative Updates

Airway Clearance Revenue Decline
Third-quarter AffloVest revenue decreased $3.4 million, or 25.1%, year-over-year to $10 million. The decline reflected temporary excess DME inventory associated with the transition to the next-generation AffloVest system.

Company Guidance

The company is maintaining full year 2026 revenue guidance of $360 million to $366 million, representing growth of approximately 9% to 11% year-over-year, and raising adjusted EBITDA guidance to $50 million to $52 million, representing growth of approximately 12% to 16% compared with $44.8 million in 2025; it expects low double-digit growth in lymphedema, full year airway clearance revenue to decline in the mid- to high single digits, meaningful sequential growth in lymphedema in the fourth quarter with a moderation in year-over-year growth, and sequential improvement in fourth-quarter airway clearance revenue with revenue remaining below the prior year. Full year modeling assumptions are GAAP gross margin of approximately 76.5%, GAAP operating expense growth of 10% to 12%, net interest income of approximately $2.4 million, an effective tax rate of approximately 28% and fully diluted weighted average shares outstanding of approximately 23 million, with adjustments of stock-based compensation expense of approximately $8.6 million, depreciation and amortization expense of approximately $7.3 million, executive transition costs of approximately $1.3 million, acquisition-related and integration costs of approximately $1.3 million and litigation-related costs of approximately $1 million.

Tactile Systems Technology Financial Statement Overview

Summary

Multi-year turnaround with sustained profitability since 2023, consistently high gross margins (~71–75%), and meaningful revenue growth. Balance sheet is a clear strength with very low leverage (debt-to-equity ~0.07–0.08) and improving ROE. Key watch items are modest TTM operating margin softening (EBIT margin ~7.3% vs ~8.7–9.8% in 2024–2025) and weaker TTM operating cash flow coverage (~0.68) despite still-positive free cash flow.

Income Statement

78Positive

Balance Sheet

86Very Positive

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue356.42M329.52M292.98M274.42M246.78M208.06M
Gross Profit264.89M247.70M216.69M195.13M175.98M148.21M
EBITDA42.47M39.02M32.37M26.42M-6.42M1.41M
Net Income23.82M19.09M16.96M28.52M-17.87M-11.81M
Balance Sheet
Total Assets291.29M273.94M297.92M281.44M255.00M244.27M
Cash, Cash Equivalents and Short-Term Investments75.11M83.45M108.91M75.23M38.06M40.71M
Total Debt17.07M15.96M45.11M50.38M72.23M80.61M
Total Liabilities64.04M55.04M81.33M87.80M133.60M116.04M
Stockholders Equity227.25M218.90M216.60M193.64M121.40M128.23M
Cash Flow
Free Cash Flow28.96M40.43M38.15M33.37M3.29M276.00K
Operating Cash Flow32.19M42.81M40.66M35.85M5.21M2.63M
Investing Cash Flow-12.56M-2.54M-2.50M-2.48M-1.91M-82.18M
Financing Cash Flow-10.49M-51.20M-4.82M5.73M-9.60M59.93M

Tactile Systems Technology Technical Analysis

Technical Analysis SentimentPositive
Last Price26.37

Price Trends

50DMA23.45Positive
100DMA25.22Positive
200DMA25.68Positive

Market Momentum

MACD1.02Negative
RSI61.17Neutral
STOCH59.53Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCMD, the sentiment is Positive. The current price of 26.37 is above the 20-day moving average (MA) of 24.98, above the 50-day MA of 23.45, and above the 200-day MA of 25.68, indicating a bullish trend. The MACD of 1.02 indicates Negative momentum. The RSI at 61.17 is Neutral, neither overbought nor oversold. The STOCH value of 59.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCMD.

Tactile Systems Technology Risk Analysis

Tactile Systems Technology disclosed 74 risk factors in its most recent earnings report. Tactile Systems Technology reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Failure to effectively implement technology initiatives or anticipate future technology needs or demands could adversely affect our business or financial results.Q4, 2025
2.Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearances, approvals or certification for our products or to manufacture, market or distribute our products after clearance, approval or certification is obtained.Q4, 2025
3.Changes in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, authorized or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could adversely impact our business.Q4, 2025

Tactile Systems Technology Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TCMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ELMDELMD76Outperform$188.82M15.9823.73%―14.12%47.72%
TCMDTCMD75Outperform$590.72M25.0710.73%―14.41%34.35%
INFUINFU70Outperform$296.30M31.3115.77%―2.40%76.01%
ENOVENOV58Neutral$1.61B-2.98-35.53%―3.28%62.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MYOMYO51Neutral$40.90M-2.98-208.07%―9.27%-22.32%
AHCOAHCO49Neutral$1.06B-2.59-28.90%―-3.17%-636.28%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%TCMDENOVELMDINFUMYOAHCODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TCMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TCMDTactile Systems Technology26.373.1813.71%
ENOVEnovis Corporation27.92-0.32-1.13%
ELMDElectromed23.10-1.42-5.79%
INFUInfuSystem Holdings, Inc.14.795.4858.86%
MYOMyomo Inc1.020.3041.67%
AHCOAdapthealth7.73-1.37-15.05%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026